Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study

Ramez N. Eskander, James Kauderer, Krishnansu S. Tewari, Robert S. Mannel, Robert E. Bristow, David M. O'Malley, Stephen C. Rubin, Gretchen E. Glaser, Chad A. Hamilton, Keiichi Fujiwara, Warner King Huh, Frederick Ueland, Jean Marie Stephan, Robert A. Burger

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Purpose: We sought to determine the level of concordance among surgeons' assessment of residual disease (RD) and pre-treatment computed tomography (CT) findings among women who underwent optimal surgical cytoreduction for advanced stage ovarian cancer. Methods: This is a post-trial ad hoc analysis of a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction. All subjects underwent imaging of the chest/abdomen/pelvis to establish a post-surgical baseline prior to the initiation of chemotherapy. Information collected on trial was utilized to compare surgeon's operative assessment of RD, to pre-treatment imaging. Results: Of 1873 enrolled patients, surgical outcome was described as optimal (RD ≤ 1 cm) in 639 subjects. Twelve patients were excluded as they did not have a baseline, pretreatment imaging, leaving 627 participants for analysis. The average interval from surgery to baseline scan was 26 days (range: 1–109). In 251 cases (40%), the post-operative scan was discordant with surgeon assessment, demonstrating RD > 1 cm in size. RD > 1 cm was most commonly identified in the right upper quadrant (28.4%), retroperitoneal para-aortic lymph nodes (RD > 1.5 cm; 28.2%) and the left upper quadrant (10.7%). Patients with RD > 1 cm on pre-treatment CT (discordant) exhibited a significantly greater risk of disease progression (HR 1.30; 95% CI 1.08–1.56; p = 0.0059). Conclusions: Among patients reported to have undergone optimal cytoreduction, 40% were found to have lesions >1 cm on postoperative, pretreatment imaging. Although inflammatory changes and/or rapid tumor regrowth could account for the discordance, the impact on PFS and distribution of RD may suggest underestimation by the operating surgeon.

Original languageEnglish
Pages (from-to)525-530
Number of pages6
JournalGynecologic Oncology
Volume149
Issue number3
DOIs
StatePublished - Jun 2018

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Bevacizumab/therapeutic use
  • Carboplatin/administration & dosage
  • Carcinoma, Ovarian Epithelial
  • Cytoreduction Surgical Procedures/methods
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Neoplasm, Residual/diagnosis
  • Neoplasms, Glandular and Epithelial/diagnosis
  • Ovarian Neoplasms/diagnosis
  • Paclitaxel/administration & dosage
  • Young Adult

Fingerprint

Dive into the research topics of 'Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study'. Together they form a unique fingerprint.

Cite this